Skip to main content
Elsevier
View Cart
My account

Books in Pharmaceutical sciences

Elsevier's Pharmaceutical Sciences collection helps pharmaceutical scientists striving to optimize drug design and improve healthcare outcomes by offering comprehensive coverage of every aspect of drug development, integrating disciplines like organic chemistry, biology, and biotechnology. Focused on safety, efficacy, and formulation design, it includes specialized fields such as Clinical Pharmacology and Translational Research, providing valuable insights into the latest advancements in drug discovery.

BooksJournals

    • The Law and Ethics of the Pharmaceutical Industry

      • 1st Edition
      • November 4, 2005
      • M.N.G. Dukes
      • English
      • Paperback
        9 7 8 0 4 4 4 5 4 5 8 5 5
      • Hardback
        9 7 8 0 4 4 4 5 1 8 6 8 2
      • eBook
        9 7 8 0 0 8 0 4 5 9 3 6 3
      As one of the most massive and successful business sectors, the pharmaceutical industry is a potent force for good in the community, yet its behaviour is frequently questioned: could it serve society at large better than it has done in the recent past? Its own internal ethics, both in business and science, may need a careful reappraisal, as may the extent to which the law - administrative, civil and criminal - succeeds in guiding (and where neccessary contraining) it. The rules of behavior that may be considered to apply to today's pharmaceutical industry have emerged over a very long period and the process goes on. Even the immensely detailed standards for quality, safety and efficacy laid down in drug law and regulation during the second half of the twentieth century have their limitations as tools for ensuring that the public interest is well served. In particular, national and regional regulatory agencies are heavily dependent on industrial data for their decision-making, their standards and competence vary, and even the existing network of agencies does not cover the entire world. What is more there are many areas of law and regulation affecting the industry, concerning for example the pricing of medicines, the conduct of clinical studies, the health protection of workers and concern for the environment. In some fields it is indeed hardly possible to maintain standards through regulation.Professor N.M. Graham Dukes, a physician and lawyer with long term experience in industrial research management, academic study and international drug policy, provides here a powerfully documented analysis into the way this industry thinks, acts, and is viewed, and examines the current trends pointing to change.

    • Handbook of Pharmaceutical Analysis by HPLC

      • 1st Edition
      • Volume 6
      • February 9, 2005
      • Satinder Ahuja + 1 more
      • English
      • Hardback
        9 7 8 0 1 2 0 8 8 5 4 7 3
      • eBook
        9 7 8 0 0 8 0 4 5 5 1 8 1
      High pressure liquid chromatography–frequ... called high performance liquid chromatography (HPLC or, LC) is the premier analytical technique in pharmaceutical analysis and is predominantly used in the pharmaceutical industry. Written by selected experts in their respective fields, the Handbook of Pharmaceutical Analysis by HPLC Volume 6, provides a complete yet concise reference guide for utilizing the versatility of HPLC in drug development and quality control. Highlighting novel approaches in HPLC and the latest developments in hyphenated techniques, the book captures the essence of major pharmaceutical applications (assays, stability testing, impurity testing, dissolution testing, cleaning validation, high-throughput screening).

    • Treatment of Leukemia and Lymphoma

      • 1st Edition
      • Volume 51
      • September 20, 2004
      • David A. Scheinberg + 1 more
      • English
      New Treatments of Leukemia and Lymphoma describes the most important advances in the therapy of hematopoietic cancers that have been derived from recent discoveries in cancer cell biology, kinase biochemistry, and immunology. Detailed descriptions of the large number of new and effective agents that have recently become available for the treatment of leukemias and lymphomas as well as an understanding of their mechanisms of action and their integration into current therapy are provided. A number of experimental drug reagents currently in clinical investigation are also discussed. The therapies include conventional anti-metabolites, monoclonal antibodies directed to cell surface receptors, antibodies tagged with toxins and radiopharmaceuticals... inhibitors of specific kinases, stem cell transplants, and engineered T-cells designed to selectively target hematopoietic cancers. The contents of the book will allow practitioners and investigators alike to understand what is current and state of the art as well as what to look for in the future.

    • Profiles of Drug Substances, Excipients and Related Methodology

      • 1st Edition
      • Volume 30
      • December 19, 2003
      • English
      • Paperback
        9 7 8 0 1 2 4 0 1 5 4 3 2
      • eBook
        9 7 8 0 0 8 0 5 2 2 6 3 0
      Whilst following in the footsteps of previous volumes by presenting comprehensive reviews of drug substances and additional materials, this title also heralds a significant expansion of the scope of the series. Traditional contributions will now also be augmented by publication of critical review chapters that summarize information related to the characterization of drug substances and excipients. This change is required to better meet the needs of the pharmaceutical communtiy and to allow the development of a timely vehicle for publishing review materials on this topic.The scope of the Profiles series will encompass review articles and database compilations that fall within one of the following six broad categories: Physical profiles of drug substances and excipients; Analytical profiles of drug substances and excipients; Drug metabolism and pharmacokinetic profiles of drug substances and excipients; Methodologoy related to the characterization of drug substances and excipients; Methods of chemical synthesis; and Reviews of the uses and applications for individual drug substances, classes of drug substances, or excipients.

    • Advances in Antiviral Drug Design

      • 1st Edition
      • Volume 4
      • December 17, 2003
      • E. De Clercq
      • English
      • Hardback
        9 7 8 0 4 4 4 5 0 6 0 2 3
      • Paperback
        9 7 8 0 4 4 4 5 4 7 7 2 9
      • eBook
        9 7 8 0 0 8 0 5 2 2 2 6 5
      The fourth volume of Advances in Antiviral Drug Design is keeping up with the recent progress made in the broad field of antiviral drug research and encompasses six specific directions that have opened new avenues for the treatment of HIV and other virus infections.First, as the introductory chapter, the different new anti-HIV agents that are now in preclinical or clinical development are reviewed by E. De Clercq. This includes new NRTIs, NNRTIs and PIs, but also HIV entry/fusion inhibitors as well as integrase inhibitors, and some of these agents, such as the NRTI emtricitabine [(-)FTC] and the PI atazanavir, may soon be licensed for clinical use.Second, high expectations are vested in the potential therapeutic usefulness of inhibitors of HIV integration, a point of no return in the life cycle of HIV, and this approach is highlighted by D.J. Hazuda and S.D. Young.Third, as all currently available PIs can be described as "peptidomimetic", and, therefore, expected to demonstrate overlapping virus-drug resistance and side effect profiles, it would be interesting to see how a non-peptidic protease inhibitor such as tipranavir behaves, and this is covered by D. Mayers, K. Curry, V. Kohlbrenner and S. McCallister.Fourth, neuraminidase inhibitors such as zanamivir (that has to be inhaled) and oseltamivir (that can be administered via the oral route) have gained a definitive status as antiviral drugs useful for both therapy and prophylaxis of influenza A and B virus infections; as they target a specific influenza viral enzyme, neuraminidase (or sialidase), they may be expected to block newly emerging influenza viruses as well, and the design of neuraminidase inhibitors has received due attention of H. Jin and C.U. Kim.Fifth, while the major current efforts in antiviral drug development have shifted from herpesviruses towards HIV and hepatitis viruses [hepatitis B virus (HBV), hepatitis C virus (HCV)], it is interesting to note that by switching from the classical five-membered sugar or acyclic nucleoside strategy, J. Wang, M. Froeyen and P. Herdewijn have gone "upstream" in designing six-membered carbocyclic nucleosides as potential anti-herpesvirus agents.Sixth, following up on the nucleotide prodrug strategy introduced above under ix, to deliver the biologically active nucleotides inside the cells, C. Meier has elaborated on a particular class of such pronucleotides, namely that of the cyclosaligenyl pronucleotides, an approach that should have far reaching implications for compounds effective against HIV, HBV and other viruses.The six topics covered in this fourth volume of Advances in Antiviral Drug Design are in the front line of the present endeavors towards the design and development of new therapeutic agents for virus infections. They pertain to the combat against three of the most important viral pathogens of current times: HIV, HBV, influenza virus and herpesviruses.

    • Handbook of Isolation and Characterization of Impurities in Pharmaceuticals

      • 1st Edition
      • Volume 5
      • June 26, 2003
      • Satinder Ahuja + 1 more
      • English
      • Hardback
        9 7 8 0 1 2 0 4 4 9 8 2 8
      • eBook
        9 7 8 0 0 8 0 5 0 7 7 6 7
      The United States Food and Drug Administration (FDA) and other regulatory bodies around the world require that impurities in drug substance and drug product levels recommended by the International Conference on Harmonisation (ICH) be isolated and characterized. Identifying process-related impurities and degradation products also helps us to understand the production of impurities and assists in defining degradation mechanisms. When this process is performed at an early stage, there is ample time to address various aspects of drug development to prevent or control the production of impurities and degradation products well before the regulatory filing and thus assure production of a high-quality drug product.This book, therefore, has been designed to meet the need for a reference text on the complex process of isolation and characterization of process-related (synthesis and formulation) impurities and degradation products to meet critical requlatory requirements.It's objective is to provide guidance on isolating and characterizing impurities of pharmaceuticals such as drug candidates, drug substances, and drug products. The book outlines impurity identification processes and will be a key resource document for impurity analysis, isolation/synthesis, and characterization.

    • Ethnomedicine and Drug Discovery

      • 1st Edition
      • Volume 1
      • March 1, 2002
      • M.M. Iwu + 1 more
      • English
      • Paperback
        9 7 8 0 4 4 4 5 4 0 0 6 5
      • eBook
        9 7 8 0 0 8 0 5 3 1 2 5 0
      The emergence of new infectious, chronic and drug resistant diseases have prompted scientists to look towards medicinal plants as agents for treatment and prevention. This book provides an interphase between ethnomedical and ethnobotanical approaches to new drug discovery and advances in biotechnology and molecular science that has made it increasingly feasible to transform traditional medicines into modern drugs. These novel approaches also raise new issues and the volume explores economic, ethical and policy considerations of drug development based on indigenous knowledge or traditional medicine.This work also features standardization and development of phytomedicines for major therapeutic indications, including emerging infectious diseases affecting developing and developed countries.The publication provides state-of-the-art information on the most innovative science, the research, the industry, the market, and the future of ethnomedicine and drug discovery.

    • Handbook of Modern Pharmaceutical Analysis

      • 1st Edition
      • Volume 3
      • July 26, 2001
      • Satinder Ahuja + 1 more
      • English
      • Hardback
        9 7 8 0 1 2 0 4 5 5 5 5 3
      • eBook
        9 7 8 0 0 8 0 4 8 8 9 2 9
      This book describes the role modern pharmaceutical analysis plays in the development of new drugs. Detailed information is provided as to how the quality of drug products is assured from the point of discovery until the patient uses the drug. Coverage includes state-of-the-art topics such as analytics for combinatorial chemistry and high-throughput screening, formulation development, stability studies, international regulatory aspects and documentation, and future technologies that are likely to impact the field. Emphasis is placed on current, easy-to-follow methods that readers can apply in their laboratories.No book has effectively replaced the very popular text, Pharmaceutical Analysis, that was edited in the 1960s by Tak Higuchi. This book will fill that gap with an up-to-date treatment that is both handy and authoritative.

    • Receptor Chemistry Towards the Third Millennium

      • 1st Edition
      • Volume 31
      • May 31, 2000
      • M. Gianella + 3 more
      • English
      • Paperback
        9 7 8 0 4 4 4 5 3 9 6 6 3
      • eBook
        9 7 8 0 0 8 0 5 4 0 4 0 5
      Receptor Chemistry Towards the Third Millennium is the result of papers presented at the 12th Camerino-Noordwijker... Symposium, held in Camerino, Italy in September 1999. Although much is known about the way ligands interact with receptors, which have now been isolated, characterized and cloned, many aspects still remain to be explored. In particular, differentiation into distinct subpopulations and the multiplicity of transduction processes offer more specific targets in the search for new drugs.This book will be of interest to medicinal chemists, pharmacologists, biochemists and neurologists and will also be a valuable source of reference for medical students and postgraduate students in related fields.

    • Controlled Release Veterinary Drug Delivery

      • 1st Edition
      • July 20, 2000
      • Michael J. Rathbone + 1 more
      • English
      • Hardback
        9 7 8 0 4 4 4 8 2 9 9 2 4
      • Paperback
        9 7 8 0 4 4 4 5 4 6 3 8 8
      • eBook
        9 7 8 0 0 8 0 5 2 9 9 7 4
      Many controlled release veterinary drug delivery systems (CRVDDS) are presently in use, and recently there has been a host of new CRVDDS within veterinary medicine. The challenges of this area of drug delivery arise from the unique anatomy and physiology of the target animal, the cost constraints associated with the value of the animal being treated and the extended periods of time that delivery must be sustained for (often measured in months).The purpose of this book is to introduce the reader to the unique opportunities and challenges of the field of CRVDDS and to explain and discuss the basic controlled release principles underlying the development of CRVDDS. Its aim is to provide an overview of many of the areas where CRVVDS have application, and to highlight the opportunities and prospects for controlled release technology in the veterinary field.Controlled Release Veterinary Drug Delivery comprises chapters that provide workers in the field (and those interested in this area) with information on the design, development and assessment of a variety of CRVDDS. The book contains chapters that describe the relevant animal physiological and anatomical considerations alongside descriptions of current and emerging controlled release delivery systems for a variety of routes for drug delivery, and present overviews on the physical and chemical assessment of veterinary controlled release delivery systems.The veterinary area is abound with opportunities for the development of controlled release drug delivery technologies. It is an area of medicine that is open to the acceptance of novel drug delivery devices, and which readily encompasses the use of novel routes of administration. It is an area of many unmet needs, most of which offer opportunities and unique challenges for the innovative formulation scientist to provide solutions. This book will provide an insight into the biological, clinical and pharmaceutical challenges that face the formulation scientist in this interesting and diverse area of research.

Related subjects

Drug delivery

Drug design

Drug dispensing

Drug manufacturing and packaging

Drug metabolism disposition

Pharmaceutical analysis

Pharmaceutical biotechnology

Pharmaceutical quality control

Pharmaceutical science general

Pharmaceutical technology

Pharmacoeconomics

Pharmacoepidemiology

Pharmacotherapy

Pharmacy

Pharmacy management